Development of a Multiplex RT-qPCR Assay for Differentiation of Wild-Type and Vaccine Strains of Canine Distemper Virus
Introduction
Canine distemper virus (CDV), a member of the genus Morbillivirus within the family Paramyxoviridae, is a highly contagious pathogen responsible for a multisystemic disease in domestic dogs and a broad range of wildlife species [1, 2]. The virus causes significant morbidity and mortality, with clinical manifestations including respiratory, gastrointestinal, and neurological signs [1, 3]. Despite widespread vaccination, CDV continues to circulate globally, with outbreaks reported in vaccinated populations, raising concerns about vaccine efficacy and the emergence of new viral lineages [4, 5, 6]. The accurate differentiation between wild-type infection and post-vaccinal reactions is critical for epidemiological surveillance, outbreak management, and clinical decision-making [7, 8, 9].
Conventional diagnostic methods, such as virus isolation, immunofluorescence, and conventional RT-PCR, often fail to distinguish between field and vaccine strains [1]. The development of a multiplex real-time reverse transcription polymerase chain reaction (RT-qPCR) assay that can simultaneously detect and differentiate wild-type and vaccine CDV strains addresses this diagnostic gap [9]. This article describes the design, optimization, and validation of such an assay, focusing on target gene selection, primer and probe design, specificity testing, and clinical validation using samples from vaccinated and infected dogs.
Target Gene Selection and Rationale
The hemagglutinin (H) gene is the primary target for differentiating CDV strains due to its high genetic variability and role in host cell receptor binding [10, 11, 12]. The H protein is the major antigenic determinant and the target of neutralizing antibodies, and its gene exhibits substantial sequence divergence between vaccine strains (typically belonging to the America-1 genotype) and contemporary wild-type strains circulating in various geographic regions [4, 13, 14, 15]. Phylogenetic analyses of the H gene have revealed multiple lineages, including America-1, America-2, Europe, Arctic-like, Asia-1, Asia-2, and others, with vaccine strains predominantly clustering within the America-1 clade [16, 4, 11, 17].
The fusion (F) protein gene has also been used for phylogenetic characterization and strain differentiation, but the H gene provides greater discriminatory power due to its higher mutation rate and positive selection pressure [10, 18, 11]. Studies have demonstrated that the H gene contains lineage-specific polymorphisms and neutralizing epitopes that can be exploited for differential detection [15, 12]. For a multiplex RT-qPCR assay, the H gene is the optimal target because it allows for the design of probes that specifically recognize conserved regions within vaccine strains (e.g., Rockborn or Onderstepoort derivatives) versus wild-type strains [16, 9, 15].
Primer and Probe Design Strategy
The design of primers and probes for a multiplex RT-qPCR assay requires careful bioinformatic analysis to ensure specificity, sensitivity, and minimal cross-reactivity. The assay typically employs a dual-probe system: one probe specific for vaccine strains and another for wild-type strains, both labeled with distinct fluorophores (e.g., FAM and HEX) to enable multiplex detection in a single reaction [9].
The design process involves the following steps:
Sequence Alignment: A comprehensive alignment of H gene sequences from vaccine strains (e.g., Rockborn, Onderstepoort, and canarypox-vectored recombinants) and a diverse panel of wild-type strains representing multiple genotypes is constructed [19, 16, 9, 11]. Sequences are obtained from public databases and published studies [13, 14, 20, 21, 22, 23, 24].
Identification of Discriminatory Regions: Conserved regions within the vaccine strain cluster that contain nucleotide polymorphisms unique to vaccine strains are identified. Conversely, regions conserved among wild-type strains but divergent from vaccine strains are selected for the wild-type probe [9, 15].
Primer and Probe Design: Primers are designed to flank the discriminatory region, ensuring efficient amplification of both target types. Probes are designed to anneal to the specific polymorphic site, with the vaccine probe matching the vaccine consensus sequence and the wild-type probe matching the wild-type consensus sequence. Mismatches at the 3' end or central region of the probe are exploited to enhance discrimination [9].
In Silico Specificity Check: Designed primers and probes are BLASTed against nucleotide databases to confirm specificity for CDV and to exclude cross-reactivity with other canine pathogens or host genomic DNA.
Multiplex Compatibility: The melting temperatures (Tm) of primers and probes are optimized to be within a narrow range (typically 58-60 degrees Celsius for primers and 5-10 degrees Celsius higher for probes). Fluorophore selection ensures spectral separation without significant overlap [9].
Assay Optimization and Analytical Performance
Optimization of the multiplex RT-qPCR assay involves titration of primer and probe concentrations, annealing temperature gradients, and magnesium chloride concentrations to achieve maximum amplification efficiency and fluorescence signal. The use of a one-step RT-qPCR master mix containing a thermostable reverse transcriptase and a hot-start DNA polymerase is standard [9].
Key analytical performance parameters include:
- Limit of Detection (LoD): The LoD is determined using serial dilutions of in vitro transcribed RNA or quantified viral RNA from cell culture supernatants. A typical LoD for a well-optimized assay is in the range of 10 to 100 RNA copies per reaction [9].
- Amplification Efficiency: Efficiency is calculated from the slope of a standard curve and should be between 90% and 110% for both targets [9].
- Dynamic Range: The linear dynamic range is assessed over several logarithms of RNA concentration, typically from 10^1 to 10^7 copies per reaction [9].
- Repeatability and Reproducibility: Intra-assay and inter-assay coefficients of variation (CV) for cycle threshold (Ct) values are calculated using replicate samples. CV values below 5% are considered acceptable [9].
Specificity Testing and Cross-Reactivity
Specificity testing is a critical component of assay validation. The multiplex RT-qPCR assay must be tested against a panel of related and unrelated pathogens to confirm the absence of cross-reactivity. This panel should include:
- Other Canine Viruses: Canine parvovirus type 2, canine adenovirus type 1 and 2, canine parainfluenza virus, canine coronavirus, and canine herpesvirus [25, 9].
- Bacterial Pathogens: Bordetella bronchiseptica, Streptococcus spp., and other common respiratory or enteric bacteria.
- Host Genomic DNA: Extracted from uninfected canine tissues or cell lines.
The assay should demonstrate 100% specificity, with no amplification signals detected for non-target pathogens [9]. Additionally, the assay must be tested against a panel of well-characterized CDV strains, including multiple vaccine strains (e.g., Rockborn, Onderstepoort, and canarypox-vectored recombinants) and a geographically diverse set of wild-type strains [19, 16, 14, 9, 26, 6]. The vaccine-specific probe should only produce a signal with vaccine strains, and the wild-type probe should only produce a signal with field strains. Mixed infections, which can occur in vaccinated animals exposed to wild-type virus, should yield signals from both probes [9].
Clinical Validation Using Field Samples
Clinical validation is performed using samples from dogs with known vaccination and infection status. Sample types include whole blood, conjunctival swabs, nasal swabs, urine, and feces [27, 9, 1]. The validation cohort should include:
- Vaccinated Healthy Dogs: Samples collected at various time points post-vaccination to detect vaccine strain RNA and assess the duration of vaccine virus shedding [28, 29, 7, 8].
- Naturally Infected Dogs: Samples from dogs with clinical signs consistent with distemper and confirmed positive by conventional RT-PCR or virus isolation [25, 13, 21, 22].
- Dogs with Post-Vaccinal Distemper: Cases where clinical signs appear shortly after vaccination and vaccine strain involvement is suspected [29, 7, 8].
The multiplex RT-qPCR assay results are compared with those from reference methods, such as conventional RT-PCR followed by sequencing or a previously validated singleplex RT-qPCR [9]. Diagnostic sensitivity and specificity are calculated using a 2x2 contingency table. A high degree of concordance (kappa value > 0.8) between the multiplex assay and reference methods is expected [9].
Workflow and Decision Tree
The following Mermaid diagram illustrates the workflow for the multiplex RT-qPCR assay for CDV strain differentiation.
graph TD
A[Clinical Sample Collection], > B[RNA Extraction]
B, > C[Multiplex RT-qPCR Setup]
C, > D[Amplification and Detection]
D, > E{Signal Interpretation}
E, >|Vaccine Probe Positive Only| F[Vaccine Strain Detected]
E, >|Wild-Type Probe Positive Only| G[Wild-Type Strain Detected]
E, >|Both Probes Positive| H[Mixed Infection Detected]
E, >|No Signal| I[CDV RNA Not Detected]
F, > J[Report: Post-Vaccinal Shedding or Vaccine-Associated Disease]
G, > K[Report: Wild-Type Infection]
H, > L[Report: Co-Infection with Vaccine and Wild-Type Strains]
I, > M[Consider Alternative Diagnosis or Repeat Testing]
Interpretation of Results and Clinical Implications
The ability to differentiate between wild-type and vaccine strains of CDV has direct clinical and epidemiological implications. Detection of vaccine strain RNA in a clinically ill dog shortly after vaccination may indicate a post-vaccinal reaction, particularly if the vaccine is a modified-live virus (MLV) product [29, 7, 8]. MLV vaccines can occasionally cause disease, especially in immunocompromised animals or when administered at inappropriate ages [28, 8]. Conversely, detection of wild-type CDV in a vaccinated dog suggests vaccine failure due to factors such as maternal antibody interference, improper storage or administration, or infection with a heterologous strain not adequately covered by the vaccine [4, 5, 6].
The multiplex RT-qPCR assay also facilitates epidemiological studies by enabling large-scale surveillance of circulating wild-type strains and monitoring the persistence and spread of vaccine-derived viruses in the environment [4, 9]. This information is valuable for updating vaccination strategies and developing new vaccines that provide broader protection against diverse CDV lineages [10, 15, 12].
Limitations and Considerations
While the multiplex RT-qPCR assay is a powerful tool, certain limitations must be acknowledged. The assay's discriminatory power depends on the conservation of the targeted polymorphisms. The emergence of new wild-type strains or the use of novel vaccine vectors (e.g., canarypox-vectored recombinants) may require periodic reassessment and redesign of primers and probes [19, 4, 26]. Additionally, the assay cannot distinguish between different wild-type genotypes, which may require subsequent sequencing for phylogenetic characterization [13, 14, 20, 21, 23]. The presence of PCR inhibitors in certain sample types (e.g., feces) can lead to false-negative results, necessitating the inclusion of an internal positive control [9].
Conclusion
The development of a multiplex RT-qPCR assay for the differentiation of wild-type and vaccine strains of CDV represents a significant advancement in veterinary molecular diagnostics. By targeting the hypervariable H gene and employing a dual-probe strategy, the assay provides rapid, sensitive, and specific discrimination between infection and vaccination. This capability is essential for accurate diagnosis, effective outbreak management, and informed vaccination policy. The assay's integration into routine diagnostic workflows, alongside other molecular tools such as those described in related articles on Multiplex RT-qPCR for Simultaneous Detection of Canine Distemper Virus, Canine Parvovirus Type 2, and Canine Adenovirus Type 2 in Clinical Samples and High-Resolution Melting Analysis (HRMA) for Rapid Genotyping of Canine Distemper Virus Strains in Clinical Samples, will enhance the capacity of veterinary laboratories to combat this persistent pathogen.
References
[1] Karki M, Rajak KK, Singh RP. Canine morbillivirus (CDV): a review on current status, emergence and the diagnostics. Virusdisease. 2022. URL: https://pubmed.ncbi.nlm.nih.gov/36039286/
[2] Kadam RG, Karikalan M, Siddappa CM, et al. Molecular and pathological screening of canine distemper virus in Asiatic lions, tigers, leopards, snow leopards, clouded leopards, leopard cats, jungle cats, civet cats, fishing cat, and jaguar of different states, India. Infect Genet Evol. 2022. URL: https://pubmed.ncbi.nlm.nih.gov/35051653/
[3] Shi N, Zhang L, Yu X, et al. Insight Into an Outbreak of Canine Distemper Virus Infection in Masked Palm Civets in China. Front Vet Sci. 2021. URL: https://pubmed.ncbi.nlm.nih.gov/34805333/
[4] Candela MG, Wipf A, Ortega N, et al. Tracking the Spatial and Functional Dispersion of Vaccine-Related Canine Distemper Virus Genotypes: Insights from a Global Scoping Review. Viruses. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40872760/
[5] Menezes KMF, Dábilla N, Souza M, et al. Identification of a new polymorphism on the wild-type canine distemper virus genome: could this contribute to vaccine failures? Braz J Microbiol. 2023. URL: https://pubmed.ncbi.nlm.nih.gov/37140816/
[6] Liu Y, Liu C, Ding H, et al. A highly virulent canine distemper virus strain isolated from vaccinated mink in China. Virus Genes. 2021. URL: https://pubmed.ncbi.nlm.nih.gov/33950332/ *** Disclaimer: This article is for educational and informational purposes only. It is not intended to substitute for professional veterinary advice, diagnosis, treatment, or regulatory guidance. Always consult a licensed veterinarian or qualified specialist regarding animal health, disease diagnosis, and therapeutic decisions.
[7] Rätsep E, Ojkic D. Canine distemper virus infection of vaccinal origin in a 14-week-old puppy. J Vet Diagn Invest. 2024. URL: https://pubmed.ncbi.nlm.nih.gov/38362661/
[8] Pekkarinen HM, Karkamo VK, Vainio-Siukola KJ, et al. Post-vaccinal distemper-like disease in two dog litters with confirmed infection of vaccine virus strain. Comp Immunol Microbiol Infect Dis. 2024. URL: https://pubmed.ncbi.nlm.nih.gov/38142559/
[9] Sui P, Sun Y, Shi Y, et al. Establishment and evaluation of a multiplex real-time RT-PCR for quantitative and differential detection of wild-type canine distemper virus from vaccine strains. Heliyon. 2023. URL: https://pubmed.ncbi.nlm.nih.gov/37662817/
[10] Khosravi M, Gharib FZ, Bakhshi A. Phylogenetic and molecular analysis of hemagglutinin gene and Fsp-coding region of canine distemper virus: Insight into novel vaccine development. Comp Immunol Microbiol Infect Dis. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/39827673/
[11] Wang H, Guo H, Hein VG, et al. The evolutionary dynamics history of canine distemper virus through analysis of the hemagglutinin gene during 1930-2020. Eur J Wildl Res. 2023. URL: https://pubmed.ncbi.nlm.nih.gov/37252648/
[12] Bi Z, Wang W, Xia X. Structure and function of a novel lineage-specific neutralizing epitope on H protein of canine distemper virus. Front Microbiol. 2022. URL: https://pubmed.ncbi.nlm.nih.gov/36713169/
[13] Doan HTT, Nguyen KT, Do RT, et al. Phylogenetic and sequence analysis of the co-circulating lineages in the canine distemper virus complexity from Northern Vietnam (2017-2023). Vet Res Commun. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40310558/
[14] Ariyama N, Agüero B, Bennett B, et al. Genetic Characterization of Canine morbillivirus (Canine Distemper Virus) Field Strains in Dogs, Chile, 2022-2023. Transbound Emerg Dis. 2024. URL: https://pubmed.ncbi.nlm.nih.gov/40303179/
[15] Wang W, Bi Z, Liu Y, et al. Development of a monoclonal antibody recognizing novel linear neutralizing epitope on H protein of canine distemper virus vaccine strains (America-1 genotype). Int J Biol Macromol. 2023. URL: https://pubmed.ncbi.nlm.nih.gov/37391002/
[16] Lanszki Z, Bányai K, Bogdán Á, et al. Completion of the Genome Sequence of a Historic CDV Vaccine Strain, Rockborn: Evolutionary and Epidemiologic Implications. Vet Sci. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41600737/
[17] Koç BT, Akkutay-Yoldar Z, Oğuzoğlu TÇ. New members to Arctic-like lineage of canine distemper virus from Turkey. Comp Immunol Microbiol Infect Dis. 2021. URL: https://pubmed.ncbi.nlm.nih.gov/34147825/
[18] Saltık HS, Atlı K. Approaches to identify canine distemper virus with neurological symptoms on the basis of molecular characterization of hemagglutinin and fusion genes. Virus Genes. 2023. URL: https://pubmed.ncbi.nlm.nih.gov/37261699/
[19] Shafik NG, Khafagy HA, Mohamed AAEM, et al. Evaluation of a canarypox-vectored recombinant vaccine expressing canine distemper virus H gene using multiplex real time RT-PCR. J Immunol Methods. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41974220/
[20] Glišić D, Kuručki M, Ćirović D, et al. Molecular analysis of canine distemper virus H gene in the golden jackal (Canis aureus) population from Serbia. BMC Vet Res. 2024. URL: https://pubmed.ncbi.nlm.nih.gov/39306660/
[21] Van TM, Le TQ, Tran BN. Phylogenetic characterization of the canine distemper virus isolated from veterinary clinics in the Mekong Delta, Vietnam. Vet World. 2023. URL: https://pubmed.ncbi.nlm.nih.gov/37576774/
[22] Truong QL, Duc HM, Anh TN, et al. Isolation and genetic characterization of canine distemper virus in domestic dogs from central and northern provinces in Vietnam. Res Vet Sci. 2022. URL: https://pubmed.ncbi.nlm.nih.gov/36347064/
[23] Giacinti JA, Pearl DL, Ojkic D, et al. Genetic characterization of canine distemper virus from wild and domestic animal submissions to diagnostic facilities in Canada. Prev Vet Med. 2022. URL: https://pubmed.ncbi.nlm.nih.gov/34785439/
[24] da Costa VG, Saivish MV, de Oliveira PG, et al. First complete genome sequence and molecular characterization of Canine morbillivirus isolated in Central Brazil. Sci Rep. 2021. URL: https://pubmed.ncbi.nlm.nih.gov/34158515/
[25] Antiya SP, Patel AC, Sharma KK, et al. Molecular detection of enteric viruses in symptomatic and asymptomatic dogs in Gujarat, India. Comp Immunol Microbiol Infect Dis. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40381481/
[26] George AM, Wille M, Wang J, et al. A novel and highly divergent Canine Distemper Virus lineage causing distemper in ferrets in Australia. Virology. 2022. URL: https://pubmed.ncbi.nlm.nih.gov/36228351/
[27] Lanszki Z, Islam MS, Shikder MF, et al. Snapshot study of canine distemper virus in Bangladesh with on-site PCR detection and nanopore sequencing. Sci Rep. 2024. URL: https://pubmed.ncbi.nlm.nih.gov/38649415/
[28] Loukeri S, Senseby F, Benizeau E, et al. Efficacy of a Modified-Live Virus Combination Vaccine (CDV, CAV, CPV, CPiV), Canigen(TM) DHPPi, in Puppies Vaccinated at Six Weeks of Age. Viruses. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41472276/
[29] Gulliver E, Taylor H, Eames M, et al. Investigation of post-vaccinal canine distemper involving the Rockborn-like strain in nine puppies in New Zealand. N Z Vet J. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40204343/
[30] Jiang Y, Sun Y, Zhai B, et al. Recombinant canine distemper virus expressing virus-like particle VP2 protein of mink enteritis virus protects minks against lethal challenges of both viruses. Vet Microbiol. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40609500/
[31] Sadaula A, Manandhar P, Shrestha BK, et al. Phylogenetic analysis linked fatal neurologic disease in leopards (Panthera pardus) to Asia-5 lineage of canine distemper virus in Nepal. Virus Res. 2024. URL: https://pubmed.ncbi.nlm.nih.gov/39313099/
[32] Chang X, Su H, Ma S, et al. Transcriptome analysis of Vero cells infected with attenuated vaccine strain CDV-QN-1. Microb Pathog. 2024. URL: https://pubmed.ncbi.nlm.nih.gov/38971506/
[33] Guercio A, Mira F, Di Bella S, et al. Biomolecular Analysis of Canine Distemper Virus Strains in Two Domestic Ferrets (Mustela putorius furo). Vet Sci. 2023. URL: https://pubmed.ncbi.nlm.nih.gov/37368761/
[34] Feng C, Bu Y, Cai J, et al. Persistent and Severe Viral Replication in PBMCs with Moderate Immunosuppression Served an Alternative Novel Pathogenic Mechanism for Canine Morbillivirus. Microbiol Spectr. 2023. URL: https://pubmed.ncbi.nlm.nih.gov/36533959/
[35] Di Francesco CE, Smoglica C, Di Pirro V, et al. Molecular Detection and Phylogenetic Analysis of Canine Distemper Virus in Marsican Brown Bear (Ursus arctos marsicanus). Animals (Basel). 2022. URL: https://pubmed.ncbi.nlm.nih.gov/35883373/